|John Houston former Chief Science Officer was appointed CEO in September as the company prepares to head into a clinical trial.|
NEW HAVEN: Arvinas LLC, founded by Chief Scientific Officer Yale bioscience researcher and Business New Haven Health Care Hero Dr. Craig Crews announced the selection of its first candidate for clinical development as a novel treatment for metastatic castration-resistant prostate cancer (mCRPC).
ARV-110 is an orally bioavailable small molecule PROTAC (PROteolysis TArgeting Chimera) designed to target and induce the degradation of the androgen receptor (AR) protein, which plays a prominent role in the development of mCRPC.
John Houston, Ph.D., President and Chief Executive Officer of Arvinas, said "we believe that our first clinical candidate from our protein degradation platform will offer a novel therapeutic modality to patients with mCRPC, adding “we are on track to initiate a clinical study of the AR PROTAC in mCRPC patients in the second half of 2018."
According to the company “ARV-110 works by hijacking the cancer cell's natural and selective process for controlling protein levels to efficiently target androgen receptor proteins for degradation and elimination. In contrast to the traditional competitive process of target inhibition, degradation by PROTACs is iterative and can overcome increases in endogenous ligand and target expression, or mutations in the target.”